The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Pooled in vivo and in vitro CRISPR-Cas9 based screening have nominated several tumour intrinsic drivers of resistance to immunotherapy 4,8-11 , but therapeutic applications of these findings remain limited.”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“thus it is surprising that TBK1 has been nominated as a candidate immune evasion gene 4,9-11”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“CRISPR/Cas9 KO screens in murine models or engineered human cell lines testing tumor-T cell interactions identified putative novel mechanisms of immune evasion involving chromatin regulators10, TNFα signaling11, SOX412, PTPN213, and APLNR10, yet their clinical relevance is unclear.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“consistent with prior reports12, induction of CD49f, which encodes an integrin associated with epithelial-to-mesenchymal transition (EMT).”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“In previous screens, antigen-specific T cells targeting model tumor associated antigen (TAA), such as OVA, gp100, and NY-ESO-1, were used (Manguso et al., 2017; Pan et al., 2018; Patel et al., 2017).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Pan et al., 2018
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationTrapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 857
Framework for in vivo T cell screens
Milling, L. E., Markson, S. C., Tjokrosurjo, Q., Derosia, N. M., Streeter, I. S. L., Hickok, G. H., Lemmen, A. M., Nguyen, T. H., Prathima, P., Fithian, W., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230699 · Cited by 14
Self-citationBrodeur, M. N., Dopeso, H., Zhu, Y., Longhini, A. L. F., Gazzo, A. M., Sun, S., Koche, R. P., Qu, R., Rosenberg, L., Hamard, P.-J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk4851 · Cited by 13
Goswami, S., Gao, J., Basu, S., Shapiro, D. D., Karam, J. A., Tidwell, R. S. S., Ahrar, K., Campbell, M. T., Shen, Y., Trevino, A. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57009-z · Cited by 13
Self-citationEpigenomic links from metabolism—methionine and chromatin architecture
Xiao, Z., & Locasale, J. W. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.011 · Cited by 13
Jiang, W., Zeng, H., Liu, Z., Jin, K., Hu, B., Chang, Y., Liu, L., Zhu, Y., Xu, L., Wang, Z., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.11.024 · Cited by 13
Johann, P. D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12616 · Cited by 15
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Miri, S. M., Tafsiri, E., Cho, W. C. S., & Ghaemi, A. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01546-8 · Cited by 15
A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
Emran, A. A., Tseng, H., Gunatilake, D., Cook, S. J., Ahmed, F., Wang, S., Hersey, P., Gallagher, S. J., & Tiffen, J. C. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.12.038 · Cited by 13
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 13
Cai, Y., Li, X., Zhu, S., Wu, H., Nie, J., & Huang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116125 · Cited by 15
Mattes, A.-K., Gámez, M. P., Martin, E., Boryń, Ł. M., Baskaran, P., Huber, H. J., Schuler, M. J., Park, J. E., & Swee, L. K. (2023) · eLife · doi:10.7554/elife.84314 · Cited by 11
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer
Tang, R., Wang, H., & Tang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332814 · Cited by 13
D’Ambrosio, A., Bressan, D., Ferracci, E., Carbone, F. G., Mulé, P., Rossi, F., Barbieri, C., Sorrenti, E., Fiaccadori, G., Detone, T., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh4435 · Cited by 13
Tao, Y., Chen, T., Qi, S., Jia, Z., Xu, Z., Meng, J., Xu, G., Hu, H., Wang, X., Zhang, T., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00930-5 · Cited by 12
Immune responses in genomically simple SWI/SNF–deficient cancers
Leruste, A., Chauvin, C., Pouponnot, C., Bourdeaut, F., Waterfall, J. J., & Piaggio, E. (2020) · Cancer · doi:10.1002/cncr.33172 · Cited by 14
Predictors of immunotherapy benefit in Merkel cell carcinoma
Kacew, A. J., Dharaneeswaran, H., Starrett, G. J., Thakuria, M., LeBoeuf, N. R., Silk, A. W., DeCaprio, J. A., & Hanna, G. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27823 · Cited by 13
McLean, B. J., Istadi, A., Clack, T., Vankan, M., Schramek, D., Neely, G. G., & Pajic, M. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200014 · Cited by 12
Lim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 12
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11
Oya, K., Nakamura, Y., Zhenjie, Z., Tanaka, R., Okiyama, N., Ichimura, Y., Ishitsuka, Y., Saito, A., Kubota, N., Watanabe, R., et al. (2021) · Cancers · doi:10.3390/cancers13163948 · Cited by 12
Ma, J., Jin, Y., Tang, Y., & Li, L. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2021.12.003 · Cited by 11
Bursch, K. L., Goetz, C. J., Jiao, G., Nuñez, R., Olp, M. D., Dhiman, A., Khurana, M., Zimmermann, M. T., Urrutia, R. A., Dykhuizen, E. C., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107146 · Cited by 11
Liu, Z., Han, L., Ji, X., Wang, X., Jian, J., Zhai, Y., Xu, Y., Wang, F., Wang, X., & Ning, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1486652 · Cited by 11
Zhang, Z., Geng, C., Song, M., Liang, H., Zhou, K., Liu, Y., Wu, J., Huang, X., Zhou, J., Fan, J., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.027 · Cited by 13
Xiong, Y., Liu, L., Bai, Q., Xia, Y., Qu, Y., Wang, J., & Guo, J. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.09.014 · Cited by 11
Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Han, T., Wang, X., Shi, S., Zhang, W., Wang, J., Wu, Q., Li, Z., Fu, J., Zheng, R., Zhang, J., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0056 · Cited by 11
Antigen Presentation Keeps Trending in Immunotherapy Resistance
Kalbasi, A. K., & Ribas, A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0698 · Cited by 12
Chaluts, D., Dullea, J. T., Ali, M. O., Vasan, V., Devarajan, A., Rutland, J. W., Gill, C. M., Ellis, E., Kinoshita, Y., McBride, R. B., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04442-y · Cited by 11
Importance of genetic screens in precision oncology
Mulero‐Sánchez, A., Pogacar, Z., & Vecchione, L. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000505 · Cited by 12
Chromatin regulation and immune escape
Ghorani, E., & Quezada, S. A. (2018) · Science · doi:10.1126/science.aat0383 · Cited by 11
Jagani, Z., Chenail, G., Xiang, K. X., Bushold, G., Bhang, H. C., Li, A., Elliott, G., Zhu, J., Vattay, A., Gilbert, T. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/812628 · Cited by 11
Li, X., Xiong, F., Hu, Z., Qing, T., Yang, Y., Qiao, X., Peng, C., Jiang, Y., Han, M., Dong, K., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04859-8 · Cited by 10
Jin, M. C., Connolly, I. D., Ravi, K., Tobert, D. G., MacDonald, S. M., & Shin, J. H. (2024) · Neurosurgical FOCUS · doi:10.3171/2024.2.focus2417 · Cited by 10
Pan‑cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy
Cao, W., Xie, Y., Cai, L., Wang, M., Chen, Z., Wang, Z., Xv, J., Wang, Y., Li, R., Liu, X., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14577 · Cited by 12
Self-citationHu, H., Li, X., Xu, Z., Tao, Y., Zhao, L., You, H., Xu, G., Zhang, T., Zhang, Y., Fan, H., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105503 · Cited by 10
Mendonca, P. (2024) · American Journal of Cancer Research · doi:10.62347/anxs3815 · Cited by 10
Li, R., He, J., Liu, C., Jiang, Z., Qin, J., Liang, K., Ji, Z., & Zhao, L. (2025) · Theranostics · doi:10.7150/thno.100793 · Cited by 10
Zhang, Z., Zhai, M., Bao, S., Sun, X., Chen, R., Wang, B., Yang, F., Yang, L., & Zhou, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.017 · Cited by 11
Shukla, P., Dange, P. P., Mohanty, B. S., Gadewal, N. S., Chaudhari, P. R., & Sarin, R. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00505-x · Cited by 10
Zhang, J., Zhou, W., Wang, X., & Wang, L. (2018) · RSC Advances · doi:10.1039/c8ra04509g · Cited by 10
The prognostic landscape of interactive biological processes presents treatment responses in cancer
He, B., Gao, R., Lv, D., Wen, Y., Song, L., Wang, X., Lin, S., Huang, Q., Deng, Z., Wang, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.064 · Cited by 10
Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment
Xue, V. W., Wong, S. C. C., & Cho, W. C. S. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1820986 · Cited by 11
Dissecting the immunogenomic biology of cancer for biomarker development
Allen, E. M. V., & Choueiri, T. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00461-1 · Cited by 10
Bioinformatic Analysis of Prognostic and Immune-Related Genes in Pancreatic Cancer
Li, Z., Hu, C., Yang, Z., Yang, M., Fang, J., & Zhou, X. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/5549298 · Cited by 10
Structures, functions, and inhibitors of LUBAC and its related diseases
Ning, S., Luo, L., Yu, B., Mai, D., & Wang, F. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0222-508r · Cited by 11
Chen, J., Yao, C., Qiao, N., Ge, Y., Li, J., Lin, Y., & Yao, S. (2021) · Cancer Medicine · doi:10.1002/cam4.4115 · Cited by 10
Pang, L., Zhou, H.-Q., Zhang, Y.-X., Zhuang, W., Pang, F., Chen, L.-J., Liao, J., Huang, Y., Mao, T.-Q., Mai, Z.-H., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103472 · Cited by 11
Molecular Profiling Defines Three Subtypes of Synovial Sarcoma
Chen, Y., Su, Y., Cao, X., Siavelis, I., Leo, I. R., Zeng, J., Tsagkozis, P., Hesla, A. C., Papakonstantinou, A., Liu, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202404510 · Cited by 10
Self-citationFan, Y., Dan, W., Que, T., Wei, Y., Liu, B., Wang, Z., Zhang, Y., Wang, Y., Liu, T., Zhuang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202412967 · Cited by 10
Chen, D., Liu, P., Lin, J., Zang, L., Liu, Y., Zhai, S., Lu, X., Weng, Y., & Li, H. (2024) · Advanced Science · doi:10.1002/advs.202406624 · Cited by 12
Cheng, X., Zhao, H., Li, Z., Yan, L., Min, Q., Wu, Q., & Zhan, Q. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06178-y · Cited by 10
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
Berry, D., Moldoveanu, D., Rajkumar, S., Lajoie, M., Lin, T., Tchelougou, D., Sakthivel, S., Sharon, I., Bernard, A., Pelletier, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115365 · Cited by 11
Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis
Xie, J., Peng, B., Xiao, Y., Chen, X., Zhang, X., Chen, D., Song, L., Xu, M., Liao, W., & Zhang, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01024a · Cited by 10
Szarkowska, J., Cwiek, P., Szymanski, M., Rusetska, N., Jancewicz, I., Stachowiak, M., Swiatek, M., Łuba, M., Konopiński, R., Kubala, S., et al. (2021) · PubMed Central · Cited by 9
Wang, R., Chen, Y., Xie, Y., Ma, X., & Liu, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111989 · Cited by 10
Methods and resources to access mutation-dependent effects on cancer drug treatment
Yao, H., Liang, Q., Qian, X., Wang, J., Sham, P. C., & Li, M. J. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz109 · Cited by 9
Li, Y., Chen, Y., Mao, S., Kaundal, R. K., Jing, Z., Chen, Q., Wang, X., Xia, J., Liu, D., Sun, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15836-2 · Cited by 9
Chen, Y., Miao, S., & Zhao, W. (2021) · PubMed Central · Cited by 8
How CRISPR/Cas9 Gene Editing Is Revolutionizing T Cell Research
Johansen, K. H. (2021) · DNA and Cell Biology · doi:10.1089/dna.2021.0579 · Cited by 9
Hou, T., Jiang, S., Wang, Y., Xie, Y., Zhang, H., Feng, Y., Ma, F., Ma, J., Liu, X., & Hu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705406 · Cited by 9
Self-citationDouble-edged roles of IFNγ in tumor elimination and immune escape
Chen, Y., Niu, N., & Xue, J. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000113 · Cited by 8
Qian, X., Cai, J., Zhang, Y., Shen, S., Wang, M., Liu, S., Meng, X., Zhang, J., Ye, Z., Qiu, S., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00201-6 · Cited by 8
A comprehensive insights of cancer immunotherapy resistance
Das, L., & Das, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02605-8 · Cited by 9
Zervanos, D.-I., Galatou, E., Miliotou, Α. N., Theodoroula, N. F., Grigoriadis, N., & Vizirianakis, I. S. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030043 · Cited by 8
Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma
Kowalewski, A., Zdrenka, M., Grzanka, D., & Szylberg, Ł. (2020) · Cancers · doi:10.3390/cancers12113300 · Cited by 8
Vredevoogd, D. W., Apriamashvili, G., & Peeper, D. S. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100043 · Cited by 7
PBRM1 Deficiency Sensitizes Renal Cancer Cells to DNMT Inhibitor 5-Fluoro-2’-Deoxycytidine
Gu, D., Dong, K., Jiang, A., Jiang, S., Fu, Z., Bao, Y., Huang, F., Yang, C., & Wang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.870229 · Cited by 8
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00001-7 · Cited by 8
Vanni, I., Pastorino, L., Tanda, E. T., Andreotti, V., Dalmasso, B., Solari, N., Mascherini, M., Cabiddu, F., Guadagno, A., Coco, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054302 · Cited by 8
Epigenetic mechanisms in melanoma development and progression
Joo, H., Olea, X. D., Zhuang, A., Zheng, B., Kim, H., & Ronai, Z. A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.007 · Cited by 9
Courtet, K., Laizet, Y., Lucchesi, C., Bessede, A., & Italiano, A. (2020) · Biomarker Research · doi:10.1186/s40364-020-00206-3 · Cited by 8
Castillo, J. J. S., Llavata, L., Fort‐Culillas, R., Cobo, P. A., Moreno, R., Codony, C., del Muro, X. G., Alemany, R., Piulats, J. M., & Martín-Liberal, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311143 · Cited by 8
Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID
Gee, S., Nelson, N., Bornot, A., Carter, N., Cuomo, M. E., Dovedi, S. J., Smith, P. D., Gianni, D., & Baker, D. J. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220916457 · Cited by 9
Recent Progress in the Methodologies to Identify Physiological Ligands of Siglecs
Jiang, H.-S., Zhuang, S.-C., Lam, C. H., Chang, L., & Angata, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813082 · Cited by 8
Estrogen deprivation triggers an immunosuppressive phenotype in breast cancer cellsPreprint
Hühn, D., Martí‐Rodrigo, P., Mouron, S. A., Hansel, C. S., Tschapalda, K., Porębski, B., Häggblad, M., Lidemalm, L., Quintela-Fandiño, M., Puigvert, J. C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/715136 · Cited by 8
Conway, J. R., Taylor-Weiner, A. N., Braun, D. A., Bakouny, Z., Choueiri, T. K., & Allen, E. M. V. (2020) · medRxiv · doi:10.1101/2020.10.30.20222356 · Cited by 7
Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
Moreta-Moraleda, C., Queralt, C., Vendrell-Ayats, C., Forcales, S. V., & Martinez‐Balibrea, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106924 · Cited by 7
High-throughput screening for optimizing adoptive T cell therapies
Zhang, Y., Xu, Q., Gao, Z., Zhang, H., Xie, X., & Li, M. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00580-w · Cited by 8
SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression
Sun, Z., Li, Z., Wei, Y., Xu, L., Hang, X., & Kang, Y. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2801 · Cited by 9
Ikeda, O., Kikuchi, A., Tsuzuki, H., Watanabe, H., Okuyama, K., Seki, Y., Ujihara, S., Matsuda, T., Weng, J., Kawashima, T., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0108 · Cited by 7
Metabolism and Immune Suppressive Response in Liver Cancer
Caini, P., & Carloni, V. (2025) · Biomedicines · doi:10.3390/biomedicines13061461 · Cited by 8
Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression
Puviindran, B. J., Wallace, S., Ayasoufi, K., Lerner, E., & Fecci, P. E. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf006 · Cited by 9
Hou, J., Ju, C., Egan, N. A., Wei, Y., Wang, Y., Dang, M., Zhou, T., Shi, L., Zheng, N., Chen, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202507718 · Cited by 7
Uridine depletion impairs CD8⁺ T cell antitumor activity through N-glycosylation
Xiao, J., Li, Z., Ding, Y., Zhu, K., Zheng, Z., Zhang, Y., Weng, J., Wang, F., Zhang, Y., Zeng, S., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.016 · Cited by 8
Kobaisi, F., Fayyad, N., Sulpice, E., Badran, B. M., Fayyad‐Kazan, H., Rachidi, W., & Gidrol, X. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03519-6 · Cited by 7
Song, Y., Huang, J. H., Wang, K., & Li, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.935650 · Cited by 7
Tumor immune evasion: insights from CRISPR screens and future directions
Djajawi, T. M., Wichmann, J., Vervoort, S. J., & Kearney, C. J. (2023) · FEBS Journal · doi:10.1111/febs.17003 · Cited by 7
Trejo-Villegas, O. A., Heijink, I. H., & Ávila‐Moreno, F. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.026 · Cited by 7
Helal, I. M., Kamal, M. A., El‐Aziz, M. K. A., & Tayebi, H. M. E. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.9 · Cited by 10
Cell Senescence and the Genetics of Melanoma Development
Constantinou, S. M., & Bennett, D. C. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23273 · Cited by 7
Hrizat, A. S., Lin, R., Eberle-Singh, J. A., O’Neill, R., Xia, Y., Testa, J. R., Uzzo, R. G., McCue, P. A., Yang, H., & Li, L. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155774 · Cited by 7
SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell–Mediated Cytotoxicity
Tin, E., Rutella, S., Khatri, I. A., Na, Y., Yan, Y., MacLean, N., Vadakekolathu, J. N., Minden, M. D., Schimmer, A. D., Lee, J. B., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0140 · Cited by 8
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma
Fu, L., Li, S., Mei, J., Li, Z., Yang, X., Zheng, C., Li, N., Lin, Y., Cao, C., Liu, L., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02319-5 · Cited by 9
A Flexible, Pooled CRISPR Library for Drug Development Screens
Blanck, M., Budnik-Zawilska, M., Lenger, S. R., McGonigle, J. E., Martin, G. R. A., le Sage, C., Lawo, S., Pemberton, H. N., Tiwana, G. S., Sorrell, D. A., et al. (2020) · The CRISPR Journal · doi:10.1089/crispr.2019.0066 · Cited by 7
New molecular tumor markers for endometrial cancer.
Numa, F., Umayahara, K., Suehiro, Y., Suminami, Y., Oga, A., Sasaki, K., & Kato, H. (2001) · PubMed · Cited by 7
Applying CRISPR Screen in Diabetes Research
Peng, Y., & Morrow, N. (2021) · Diabetes · doi:10.2337/dbi20-0047 · Cited by 9
Li, X., Zhang, Y., Zhang, T., Zhao, L., Lin, C. G., Hu, H., & Zheng, H. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00683-2 · Cited by 6
Wu, M., Yang, S., Yang, Z., Fan, J., Lomeli, S. H., Dharanipragada, P., Moriceau, G., Damoiseaux, R. D., Kelley, M. C., Granada, C. N. P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.001 · Cited by 6
Current trends of functionalized nanomaterial-based sensors in point-of-care diagnosis
Nandini, S., Nalini, S., Bindhu, S., Sandeep, S., Karthik, C. S., Nithin, K. S., Mallu, P., & Manjunatha, J. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823788-5.00019-3 · Cited by 6
An oncogene regulating chromatin favors response to immunotherapy
Ying, L., Hu, Z., Lü, Y., Qing, T., Xiong, F., Shu, Y., Yang, Y., Qiao, X., Peng, C., Jiang, Y., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2303195 · Cited by 6
Metadata
- Authors
- Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., Long, H. W., Yuan, G.-C., Doench, J., Brown, M., Liu, X. S., & Wucherpfennig, K. W.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Astellas Pharma (Japan) (JP)
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Harvard University (US)
- Corresponding author
- Pan, Deng
- Kobayashi, Aya
- Jiang, Peng
- Liu, X. Shirley
- Wucherpfennig, Kai W.
- ORCID
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 770-775
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5953516
- OpenAlex
- W2782124401
- Cited by
- 852
- References
- 51
- Citations by year
- 2026: 39 · 2025: 96 · 2024: 92 · 2023: 107 · 2022: 123 · 2021: 117 · 2020: 143 · 2019: 86 · 2018: 47
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01CA173750)
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- SWI/SNF complex, PBRM1, immune checkpoint inhibitors, T cell-mediated killing, antitumor immunity, interferon-gamma, renal cell carcinoma, chromatin regulation
- MeSH terms
- CRISPR-Associated Protein 9, Bromodomain Containing Proteins, Animals, Bacterial Proteins, Chromosomal Proteins, Non-Histone, Cytotoxicity, Immunologic, DNA-Binding Proteins, Endonucleases, Genetic Testing, Humans, Immunotherapy, Interferon-gamma, Melanoma, Experimental, Skin Neoplasms, T-Lymphocytes, Cytotoxic, Transcription Factors, HMGB Proteins, Cell Line, Tumor, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
